Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ron Oda who wrote (889)	11/10/1998 12:18:00 PM
From: NYBellBoy	Respond to of 1060

Ron -- Thanks for posting the article! :) BellBoy

To: Ron Oda who wrote (889)	11/10/1998 1:38:00 PM
From: Ron Oda	Read Replies (1) \| Respond to of 1060

The article also talks about neuroprotective drugs. These drugs are meant to prevent the dying of retinal nerve cells. I don't believe Insite has anything like this, but I could be wrong. That is probably what Allergan is working on. I was thinking this may impact ISV-205 but that may not be the case. The article talks about high IOP not always being a predictor of Glaucoma, but I think that high IOP is still a high percentage indicator of Glaucoma. I would think ISV-205, which will hopefully prevent high IOP in many cases, would still be needed. RG